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Progress in isolation and purification of an inhibitor of sodium trans-
port. Among the potential modulators of transtubular sodium transport
is the putative natriuretic hormone. Widespread efforts are underway to
isolate this substance in pure form. The present studies describe a series
of experiments directed to this goal. Urine samples in the amount of 150
liters were taken from normal, mineralocorticoid hormone "escape"
dogs and were chromatographed through Sephadex G-25. The active
fraction of the eluate (that is, the fraction containing the inhibitor of
sodium transport) was then subjected to high pressure liquid chroma-
tography (HPLC) in four consecutive steps using three different resins.
Approximately 5% of each column eluate was diverted by use of a
stream-splitting apparatus, and the fluorescent pattern was measured
and recorded, in most instances following the addition of fluorescamine.
Based on the respective fluorescent patterns obtained from the eluates
of the successive chromatographic steps, the residual portion (95%) of
each eluate was divided into fractions, and each fraction was bioas-
sayed. In each instance only the biologically active fraction was
subjected to further purification. In the first step involving HPLC and a
cation exchange resin, six fractions were obtained. Only one was
active. When this fraction was subjected to reverse-phase chromatogra-
phy, seven new fractions emerged. Again only one was active. When it
was chromatographed using a second cation exchange resin, two
fluorometrically detectable peaks, termed N and H, were identifiable.
N exhibited spontaneous fluorescence; H exhibited fluorescamine-
dependent fluorescence. In the final step, N and H were separated and
bio-assayed individually. N was inactive; H proved to be a potent
inhibitor of sodium transport. Accumulation of H in sufficient quantity
will determine whether it is a single compound and will permit analysis
of its chemical nature.
Progrès dans l'isolement et Ia purification d'un inhibiteur du transport
de sodium. Parmi les modulateurs potentiels du transport transtubulaire
de sodium est l'hormone natriurètique présumée. Des tentatives sont en
cours pour isoler cette substance dans sa forme pure. Ce travail décrit
une série d'expériences ayant ce but. Exemples d'urine dans au total
d'150 litres aient pris provenant de chiens normaux en situation
d'échappement a l'action de l'hormone minCralocorticoIde et ont ètë
chromatographies sur Séphadex G25. La fraction active de l'éluat
(c'est-à-dire Ia fraction contenant l'inhibiteur du transport de sodium) a
ét soumise a une chromatographie liquide a haute pression (HPLC)
dans 4 étapes consécutives utilisant trois résines différentes. Approxi-
mativement 5% de l'éluat de chaque colonne a etë séparé par l'utilisa-
lion dun système de fractionnement du courant et le profil de fluores-
cence a eté mesuré et enregistré, dans Ia plupart des cas après I'addition
de fluorescamine. La portion résiduelle (95%) de chaque éluat a été
divisée en fractions et chaque fraction a été soumise a Un essai
biologique en fonction des spectres de fluorescence obtenus respective-
ment au cours des étapes chromatographiques. Seule Ia fraction biolo-
giquement active a etC soumise a une purification ultCrieure. Dans Ia
premiere étape impliquant HPLC et une résine d'échange cationique 6
fractions ont été obtenues. Une seulement était active. Quand cette
fraction a etC soumise a une chromatographie inverse, 7 nouvelles
fractions ont été recueillies. Là encore une seule était active. Quand
celle-ci a été soumise a une chromatographie au moyen d'une deuxième
rCsine d'echange cationique, 2 pics dCtectables en fluorimCtrie, dC-
signés par N et H ont été identifies. N avait une fluorescence spon-
tanée, H une fluorescence dependante de Ia fluorescamine. Dans
l'étape finale N et H ont été séparés et soumis individuellement a un
essai biologique. N était inactif, H s'est révélé un inhibiteur puissant du
transport de sodium. L'accumulation de H en quantite suffisante
permettra ultCrieurement de determiner s'il s'agit d'un compose unique
et permettra d'analyser sa nature chimique.
A growing number of investigators have been involved in the
effort to purify and characterize the putative natriuretic hor-
mone [1—6]. The progress of this search as well as a description
of the biological evidence favoring the existence of such a
hormone has been presented in a series of recent papers and
reviews [1, 4, 6—111. Our manuscript describes the results of
experiments in our laboratories directed to the isolation of an
inhibitor of sodium transport obtained from normal dogs follow-
ing "escape" from mineralocorticoid hormone and a high salt
diet. Although it is our assumption that the active substance is
the natriuretic hormone, the latter has not yet been established,
and we will refer to the inhibitor in the text as natriuretic factor
or NF.
Because the site of natriuretic hormone is unknown, most
attempts to isolate it have been performed using plasma and/or
urine samples as the source; although in some laboratories,
hypothalmic and posterior pituitary extracts and extracts from
the renal parenchyma have been employed. The initial step in
purification typically has consisted of gel filtration using Sepha-
dcx or Biogel. Thereafter, the procedures have varied consider-
ably; but at each step in separation, it is necessary to ascertain
which of the chromatographic fractions contains the biological
activity. This requirement has constituted a principal difficulty
in the efforts to purify NF, The majority of bioassays in use are
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Table 1. Purification steps of natriuretic hormone
I. Desalting on Sephadex G-25
2. Cation exchange chromatography (H-70) on HPLC system
3. Reverse phase chromatography on partisil ODS-2
4. Cation exchange (DC-4A) chromatography
5. Reverse phase chromatography on partisil ODS-2
Abbreviation used is defined: HPLC, high pressure liquid
chromatography.
qualitative and many require a relatively large proportion of
yield, thus reducing progressively the amount available for the
sequential steps employed in the attempts at isolation. Because
of this problem, we have collected large volumes of urine
samples for the execution of our studies.
Methods
The sequence of events that we followed in the studies is
listed in Table 1.
Harvesting control and mineralocorticoid
hormone "escape" urine
A colony of four healthy adult trained female mongrel dogs
was used. Each animal was maintained in an individual meta-
bolic cage. During the first 3 days, the dogs were fed a diet
containing 50 mEq of sodium daily. Beginning on the fourth day
and continuing through the tenth day, the sodium intake was
increased to 250 mEq per day; 0.1 mg of fludrocortisone was
administered twice daily. Consecutive 24-hour urine sample
collections were obtained from each dog through the full 10-day
cycle. The collections from all four dogs were pooled for days I
through 3 and were used as the control sample. "Escape" from
the minerolocorticoid hormone and high salt regimen invariably
occurred by the fifth day. Thus, the 24-hour collections from
days 6 through 10 were pooled and utilized as the source of the
natriuretic factor. At the end of the tenth day, the dogs were
restored to their regular habitat and fed normal laboratory chow
without added salt of fludrocortisone. They were allowed a rest
period of 4 days before the next cycle was initiated. Six
complete cycles were employed to obtain the desired 150 liters
of urine for study.
Initial fractionation through Sephadex G-25
The control and experimental urine pools (from days I to 3
and 6 to 10 respectively) were stored at —20° C and then
lyophilized to dryness. The dry powder was redissolved in
distilled water and stored at —80° C until used. Biologic activity
has been found to persist for at least 18 months in this
temperature. The equivalent of 66 6 hours of original urine
samples was applied to 10 x 100 cm columns packed with
Sephadex G-25. Elution was carried out at 4° C using 10 mrs'i
ammonium acetate at pH 6.8. The urine volume (UV) absorp-
tion at 280 nm and the conductivity of the effluent solutions
were monitored and recorded continuously. In accordance with
previous observations [12] the biologic activity was found to
reside in the fraction of eluate that appeared immediately after
the major salt peak. The first ten "post-salt" fractions were
collected using an automated fraction collector; the contents of
each were relyophilized and subjected to bioassay in order to
localize further the area of biologic activity (the technique of
bioassay will be described below). The activity was limited to
six of the ten "post-salt" fractions, which were then pooled and
utilized in the subsequent steps in purification.
High pressure liquid chromatography (HPLC) using a cation
exchange resin
The remaining steps in purification were performed using a
high performance liquid chromatography system which incor-
porated a device for a "discontinuous stream-sampling valve"
[13, 14].
The stream-sampling HPLC system. Briefly, the method
involves the use of two independent flow systems which split
each fraction of the column effluent into a small (less than 10%
of the total) and a large stream. The small stream is diverted to a
system designed for the measurement of fluorogenic activity,
while the major portion of each fraction is directed into the
fraction collector for bioassay and chemical analysis. Separa-
tion of the small component is accomplished by means of a
discontinuous stream-sampling valve, which directs the ali-
quots of the column effluent, at predetermined intervals, into a
mixing manifold of the fluorogenic detector system. Each
aliquot is mixed with a buffer and a fluorescamine, a fluorescent
compound which binds to active amine groups. The emitted
fluorescence, naturally occurring if fluorescamine is omitted, or
fluorescamine-dependent, is measured in a fluorometer
equipped with a flow cell. Both the spontaneous and fluoresca-
mine-dependent fluorescence may thus be measured for each
sample subjected to bioassay and purification studies [15].
The automatic monitoring system was built in our laboratory
and was modified slightly from the system described by Bohlen
et al [13]. It included a gradient mixer obtained from LKB
(Hicksville, New York), Milton Roy (Riviera Beach, Florida)
mini pumps, and a high pressure sample injection valve, Rheo-
dyne Incorporated (Berkeley, California).
Among the buffers and solvents employed, pyridine, acetic
acid, acetone, and methanol were each distilled twice. Water
was purified by a system obtained from Hydro Services and
Supplies (Durham, North Carolina). Caprylic acid, fluoresca-
mine, a 25% solution of thiodiglycol, and hydrochloric acid
were obtained from Pierce Chemical Company (Rockford,
Illinois). All other chemicals used in the preparation of reagents
or buffers were AR-grade from Mallinckrodt Chemical Works
(St. Louis, Missouri).
The cation exchange resin, H-70. The biologically active
fraction from the Sephadex G-25 eluate was subjected to cation
exchange chromatography using a prepacked 25 x 0.46 cm ID
column of H-70 cation exchange resin obtained from Hamilton
(Reno, Nevada). A 2-hour linear gradient from 0.05 M pyridine
acetic acid, pH 4, to 0.5 M pyridine acetic acid, pH 5, was used
at a flow rate of 13 ml per hour at room temperature with a back
pressure of 300 to 400 psi. The amount of the active G-25
fraction obtained from 5 hours of the initial urine sample was
dissolved in a volume of 200 pJ of water and applied to the
column. The larger component of each "cut" of the eluate was
collected in glass scintillation vials which had been pretreated
with Silicald (Clay Adams, Pasippany, New Jersey). The con-
tents of the vials were pooled into fractions based on the pattern
of fluorescence, and the fractions were lyophilized and stored at
—90° C for bioassay and, if indicated, the next step in purifica-
tion,
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details, including the criteria for a positive assay have been
described previously 116]. We also have used the natriuretic
response of the uremic rat to the intravenous administration of
test fractions. However, the results of the two assays have been
shown to coincide. The toad bladder assay is a less formidable
procedure; it offers a major advantage in a study such as the
present one, where large numbers of samples must be tested.
45 60 75 As in previous studies, a number of samples were assayed by
Time, rn/n both methods, and no discrepant results were observed.
With each successive step in purification, biologic activity
was lost, and the number of "hourly equivalents" of original
urine samples required for a positive assay increased. Identical
quantities of control fractions and biologically inactive fractions
were used.
Reverse phase chromatography
The biologically active fraction from the H-70 cation ex-
change chromatography was next subjected to reverse phase
chromatography. The material obtained from two hours of
original urine sampling was dissolved in 200 il of 0.2 M pyridine
acetate containing 2% methanol, and the solution was applied to
a 25 x 0.46 cm I.D. column containing partisil ODS-2 resin
(Whatman, Clifton, New Jersey). Each column was pumped at
25 ml per hour at room temperature in order to obtain a back
pressure at 400 to 600 psi. A 0.2 M pyridine-acetate buffer was
used for elution. A 1-hour linear gradient from 2 to 20%
methanol was used, The column eluate again was collected in
glass scintillation vials, pooled into fractions, and lyophilized.
The fractions were maintained at —90° C until they were
subjected to bioassay and to the next step in purification.
Cation exchange chromatography with DC-4A resin
The final chromatographic step involved subjecting the bio-
logically active fractions from the ODS-2 eluate to cation
exchange resin, DS-4A (obtained from Durrum Chemical Com-
pany, Palo Alto, California); 1.75 x 480 mm ID. stainless steel
columns were pumped at 4.6 ml per hour at 55° C; a back
pressure of 1,100 psi was maintained. The samples (2-hour
equivalents of original urine sampling) were applied to the
column in a volume of 110 tl of 0.2 M sodium citrate, pH 2.2,
and elution was carried out with 0.2 M sodium citrate at pH 3.2.
As in the preceding steps, the tubes of eluate were pooled into
fractions and after lyophilization, the fractions were reapplied
to the ODS-2 reverse-phase chromatographic system using the
identical technique described above in order to remove the
sodium citrate. The fractions then were re-lyophilized and
stored temporarily at —90° C.
Bioassays. The bioassay system employed has been de-
scribed in detail previously 116]. It involves the measurements
of the degree of inhibition of sodium transport across the
isolated urinary bladder of the toad, Bufo marinus. Transcellu-
lar sodium transport is measured as the short-circuit current
(SCC) using Ussing chambers with a 2 cm2 area of exposed
bladder, The fraction to be tested, which is coded, is dissolved
in a total volume of I ml of a solution which has the final
composition of anuran Ringer and is applied to the serosal
surface. The same solution, without the sample, is applied to
the mucosal surface of the bladder. The remainder of the
Figure 1 depicts the characteristic pattern of fluorescence
observed when the biologically active fraction from Sephadex
G-25 was subjected to high performance liquid chromatography
using cation exchange resin H-70. As described above, the
column eluate was stream-sampled, fluorescamine was added
automatically to the smaller stream and the fluorescence was
monitored and recorded continuously. On the basis of this
pattern of fluorescence, the eluate was divided into six fractions
designated as F-I through F-VI. The results of bioassays, of all
six fractions from six different H-70 eluates are shown in Table
2. Eight hourly equivalents of original urine samples were used.
In each experiment, inhibition of sodium transport was seen
only with fraction F-I. The results of' the bioassays using the F-I
fractions from the H-70 cation exchange columns are shown in
more detail in Table 3. The onset of inhibition of sodium
transport began after a delay of approximately 10 mm and
progressed through the remainder of the 60-mm period of
observation. The maximum inhibition of short-circuit current
was 52%. The mean inhibition for all six experiments, observed
during the final period of observation, was 38%.
No consistent or statistical changes in SCC and potential
difference (PD) were observed with the H-70 fractions of the
control urine samples (see Methods).
After completing the bioassays, all positive F-I fractions were
pooled and subjected to reverse-phase chromatography using
the partisil ODS-2 resin. Fluorescamine was added as described
above. On the basis of the relative fluorescence pattern, (Fig. 2)
the eluate was divided into six fractions, The fraction labelled 7
in the figure is the wash volume. Each fraction was tested for
biologic activity using 16 hourly equivalents of original urine
samples. The results of the assays of all the eluate fractions
from four separate columns are shown in Table 4. Once again,
only a single fraction, designated (F-I)5 was consistently active.
The maximal degree of inhibition of short-circuit current ob-
served was 33%, and the mean was 26%.
All of the positive (F-I)5 fractions were then pooled and
subjected to cation exchange chromatography with the DC-4A
resin. Relative fluorescence was measured under two condi-
tions: (1) with no fluorescamine added (Fig. 3a); and (2) with the
addition of fluorescamine (Fig. 3b). In the non-fluorescamine
study, only the fluorescamine vehicle acetone was added. Both
in the presence and absence of fluorescamine, the eluates
contained a sharp fluorescent peak at approximately 12 mm.
However, in the presence of fluorescamine, a second peak,
0 15 30
a 1000
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Fig. 1. Chromatography of' post salt" G-25 Sephadex fraction on H-70
column (0.46 x 25 cm) at 25° C. A 2-hr linear gradient from 0.05 M
pyridine acetic acid pH 4.0 to 0.5 M pyridine acetic acid, pH 5.0, was
used at a flow rate of 13 mI/h. A portion (5%) of the column effluent was
directed to the fluorescamine monitoring system. The asterisk (*)
indicates active fraction.
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Table 2. The effect of fractions from ion exchange column (H-70) on short-circuit current (SCC) and potential difference (PD) across the
isolated toad bladder°
F-I F-lI F-Ill F-IV F-V F-V1
Column no. SCC PD SCC PD SCC PD SCC PD SCC PD SCC PD
I
2
3
4
5
6
Mean
SEM
—47
—52
—42
—21
—39
—27
—38
4.8
—21
—30
—20
—14
—10
—28
—20.5
3.1
—10
—10
—5
—5
+5
—10
—5.8
2.3
—5
—3
—1
—2
—4
—8
—3.8
1.0
+7
—3
—9
—7
—9
+3
—3
2.7
—9
—7
—9
—2
—7
+14
—3.3
3.6
+7
—6
5
0
—5
+4
—0.8
2.2
+3
—8
—5
—2
—1
+10
—2.1
1.5
+2
+3
+3
+3
0
+2
+2.1
0.4
+1
0
0
0
0
—2
—0.2
0.4
+1
—5
—14
0
0
+5
—2.8
2.6
—4
0
0
0
0
+6
+0.3
1.3
a Results are expressed as percent changes in SCC and PD values after the addition of the fraction to the Ringer's solution bathing the serosal
surface. The amount of each H-70 column eluate tested was derived from 8 hrs of original urine samples (that is, 8-hr equivalents). The actual
values for SCC before adding fraction F-I are shown in Table 3. These values are not dissimilar to control values for all other experiments shown in
this table.
Table 3. Results of six experiments using fraction (F-I) from ion exchange column (H-70) on short-circuit current (SCC) across the isolated toad
bladder°
S CC C C0
Column no. SCCO 0 10 20 30 40 50 60
Fig. 2. Chromatography offraction F-I from the H-70 column on ODS-2
column (0.46 x 25 cm) at 25° C. A 1-hr linear gradient from 2% methanol
and 0.2 M pyndine acetic acid (pH 5.5) to 20% methanol in the same
buffer, was used at a flow rate of 25 mI/h. A portion (5%) of the column
effluent was directed to the fluorescamine monitoring system. Methanol
is indicated by a broken line. The asterisk (*) indicates active fraction.
which by definition is fluorescamine-dependent appeared. The
spontaneously fluorescent peak is designated as fraction N; the
fluorescamine-dependent peak is designated as fraction H. The
total quantity of residual material (44 hourly equivalents), was
then separated into two fractions, one containing peak N, the
other peak H; both were subjected to bioassay. The results
using fraction N are shown in Figure 4. A slight fall in SCC
occurred immediately after addition of the fraction, but this was
non-progressive and quite unlike the pattern seen with any of
the biologically active fractions in this or previous studies. The
results obtained with fraction H are shown in Figure 5. A
striking fall in SCC was observed. Though more marked, the
2 pattern of inhibition was closely comparable to that seen with
each of the less pure materials from the "post-salt" Sephadex
G-25 fraction through the partisil ODS-2 resin fraction. Thus,
after the addition of fraction H, there was a lag period of slightly
under 10 mm followed by a progressive fall in values for SCC
over the ensuing 40 mm of observation. The potential difference
fell in parallel with SCC; there were no changes in calculated
values for electrical resistance. After 1 hour, the Ringer's
solution containing the active fraction was removed and re-
placed with fresh Ringer free of any inhibitor. The values for
both SCC and PD stabilized showing no further decrement. The
serosal solution containing peak H was removed and stored at
4° C for several days. It was then re-assayed and the results are
included in Figure 5. Once again, striking inhibition occurred.
On this occasion, when the fraction was removed and replaced
with fresh Ringer, both SCC and PD increased toward the
control level.
Discussion
Our efforts to isolate a natriuretic hormone have been under-
way for a number of years [18, 191. Because of the lack of
information concerning the site of production of what still must
58
40
38
34
94
64
1.00 0.95 0.78 0.66 0.59 0.55 0.53
1.00 0.90 0.70 0.58 0.55 0.50 0,48
1.00 1.03 0.82 0.68 0.63 0.61 0.58
1.00 1.03 1.00 0.91 0.88 0.82 0.79
1.00 0.97 0.98 0.80 0.71 0.65 0.61
1.00 1.06 0.95 0.84 0.77 0.73 0.73
1.00 0.99 0.87 0.75 0.68 0.64 0.62
0.00 0.02 0.05 0.05 0.05 0.05 0.05
2
3
4
5
6
Mean
SEM
a Results are expressed as the ratio of short-circuit current values observed at specific times in mm (SCCI), after the addition of the fraction to the
Ringer's solution bathing the serosal surface of the bladder to the control value observed at time zero (SCC0). The amount of each H-70 eluate test-
ed was derived from 8 hrs of original urine samples (that is, 8-hr equivalents).
I 7—ta,0
a,0
a,
0
a,
a,
80
40
0
0 12 24 36 48 60 72
Time, rn/n
Purification of the natriu,v'tic factor 343
Table 4. The effect of fraction from reverse phase column (ODS-2) on short-circuit current (SCC) and potential difference (PD) across the
isolated toad bladdera
F-I F-I2 F-I3 F-I4 F-I5 F-Ic
Column no. SCC PD SCC PD SCC PD SCC PD SCC PD SCC PD
1 +14 + 3 + 6 +6 +15 +12 + 3 +2 —22 —17 +8 +3
2 +25 +26 +15 +6 +13 + 2 —13 —5 —29 —20 0 +1
3 — 2 0 — 2 —-2 0 — 3 —11 —6 —33 —25 +5 +7
4 —3 —6 —3 —6 +7 +1 —7 —9 —20 —IS 0 +1
Mean + 8.5 + 5.7 + 4.0 +1.7 + 8.7 + 3.0 — 7.0
—4.5 —26.0 —19.2 +3.2 +3
SaM 6.7 7.0 4.2 2.4 3.3 3.1 3.5 2.3 3.0 2.2 1.9 1.4
a Results are expressed as the percent of change in SCC and PD values after one addition of the fraction to the Ringer's solution bathing the sero-
sal surface. The amount of each ODS-2 column eluate tesLd was derived from 16 hrs of original urine samples (that is, 16-hr equivalents).
40
20
0
I . p p p p
Time, rn/n
Fig. 3. Chromatography of fraction (F-I)5 from ODS-2 column on DC-
4A column (1.75 x 480 mm) at 55° C. Sodium citrate in 0.2 MpH 3.2 was
used for elution at a flow rate of 4.6 mI/h. A portion (2%) of the column
effluent was directed to the fluorescamine monitoring system. Fractions
N and H were collected from 5 to IS and from 15 to 30 nun,
respectively.
be regarded as a putative hormone, we have employed urine
samples (and earlier serum) as our source of material for both
biologic and chemical experiments. Studies have been per-
formed on the saline-loaded cow and dog [20], uremic man [121,
and the normal dog undergoing mineralocorticoid hormone
"escape". In other laboratories urine samples, serum and
tissue homogenates from the kidney, and hypothalami and
pituitary glands from normal men or animals on varying levels
of salt intake have been utilized as the source for the natriuretic
hormone [1—5].
The initial preparatory step in all the studies has involved
application of the sample, concentrated by lyphilization, to
Sephadex G-25. The active fraction has consistently appeared
in a cut of the eluate which appeared after molecules as small as
urea and sodium. The natriuretic factor therefore, presumably
is retarded on the Sephadex. (Although the bioassay system
employed was based on inhibition of sodium transport across
the anuran bladder, there is, as already noted, a close correla-
tion between the antinatriferic effect, and the natriuretic effect
in unanesthetized rats.) In efforts to purify the material in the
past, we have employed a variety of chromatographic tech-
niques including Dowex-50, Biogel P-2, and descending paper
chromatography. Our studies involve the use of high pressure
liquid chromatography using a stream-sampling system and a
method of automatic monitoring that permits the detection of
either naturally occurring fluorescent compounds or fluoresca-
mine-dependent fluorescent compounds in concentrations as
low as lO2 M. At each stage of purification, it was necessary
to deploy sufficient material to determine that the biologic
activity had not been lost in the chromatographic procedure and
where in the eluate it resided. With each of the successive
chromatographic steps, biologic activity was lost; however, a
sufficient quantity of the active material persisted in the final
preparation to produce a striking degree of inhibition of sodium
transport across the isolated toad bladder. This final fraction,
designated as H, contained no detectable spontaneous fluores-
cence and only a single fluorescamine-dependent peak. This
A
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6008
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0 12 24 36 4860 0 12 24 36 48
0 10 20 30
Time, rn/n
Fig. 4. Changes of SCC across the isolated toad bladder following the
addition of 44-hr equivalents ofNfraction from DC-4A column to the
60 serosal surface (0). The serosal solution containing the fraction was
then removed and transferred to the serosal surface of another bladder
with stable values of SCC (0). Results are expressed as in Table 3.
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peak, by virtue of the fluroescamine reaction, must contain an
active amine group [211. Future studies, hopefully, will allow
the determination of its biologic significance and ultimately of
the chemical structure of the molecule responsible for the
inhibition of sodium transport.
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Fig. 5. Changes of SCC across the isolated toad bladder following
addition of H fraction representing 44-hr equivalents of original urine
from DC-4A column to the serosal surface (S). The serosal solution
containing the fraction was then removed and transferred to the serosal
surface of another bladder with stable values of SCC (0). Results are
expressed as in Table 3.
